Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2011 Aug;10(8):1117-20. doi: 10.1586/erv.11.97.

Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine.

Author information

  • 1Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam The Netherlands.


Designing an HIV-1 envelope glycoprotein (Env) that can induce broadly neutralizing antibodies in humans remains one of the great challenges in biomedical research. Monomeric gp120 has repeatedly failed to induce cross-neutralizing antibodies in clinical trials. Spearman et al. vaccinated uninfected volunteers with a trimeric gp140 protein. They found that the vaccine was safe and induced neutralizing antibody responses against the homologous virus, but not cross-neutralizing responses. The results reinforce the notion that our Env vaccine design needs to improve.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk